Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717455 · ClinicalTrials.gov registry record · Phase 1
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02717455 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 53 participants.
The verdict
NCT02717455, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-06-28 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717455
The ClinicalTrials.gov registry entry for NCT02717455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT02717455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02717455 about?
NCT02717455 is a clinical study titled "Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma". This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has re...
What is the current status of trial NCT02717455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2016-06-28. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT02717455?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT02717455?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.